Top

Published in:

01-06-2003

New approaches to the endocrine prevention and treatment of breast cancer

Authors: Anthony Howell, Sacha J. Howell, D. Gareth Evans

Published in: Cancer Chemotherapy and Pharmacology | Special Issue 1/2003

Abstract

All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.

ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131CrossRefPubMed

Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet ii:104

Buzdar A, Howell A (2001) Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 7:2620PubMed

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG (2002) American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328CrossRefPubMed

Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987PubMed

Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer. Lancet 2:282

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296CrossRefPubMed

Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451PubMed

Evans DG, Lalloo F, Shenton A, Boggis C, Howell A (2001) Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 358:889CrossRefPubMed

10.

Feinleib M (1968) Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41:315PubMed

11.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371PubMed

12.

Ginger MR, Gonzalez-Rimbau MF, Gay JP, Rosen JM (2001) Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland. Mol Endocrinol 15:1993PubMed

13.

Gnant M, Hausmaninger H, Samonigg H, Mlineritsch B, Taucher S, Luschin-Ebengreuth G, Jakesz R (2002) Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomised multicenter trial. Breast Cancer Res Treat 76 [Suppl 1]:A12

14.

Goss PE, Strasser K (2001) Chemoprevention with aromatase inhibitors—trial strategies. J Steroid Biochem Mol Biol 79:143CrossRefPubMed

15.

Gram IT, Ursin G, Spicer DV, Pike MC (2001) Reversal of gonadotrophin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 10:1117PubMed

16.

Hirayama T, Wynder EL (1962) A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 15:28

17.

Howell A, Johnston SRD (2002) Selective estrogen receptor modulators (SERMS). In: Robertson JFR, Nicholson RI, Hayes DF (eds) Endocrine therapy of breast cancer. Martin Dunitz, London, p 45

18.

Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P (1996) Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74:300

19.

Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhafer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621CrossRefPubMed

20.

Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628CrossRefPubMed

21.

Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol 19:343PubMed

22.

Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918PubMed

23.

Mettlin C (1999) Global breast cancer mortality statistics. CA Cancer J Clin 49:138PubMed

24.

Palomba S, Orio F, Morelli M, Russo T, Pellicano M, Zupi E, Lombardi G, Nappi C, Panici PL, Zullo F (2002) Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87:3603PubMed

25.

Peto R, Boreham J, Clarke M, Davies C, Beral V (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355:1822

26.

Pike MC, Daniels JR, Spicer DV (1997) A hormonal contraceptive approach to reducing breast and ovarian cancer risk: an update. Endocr Relat Cancer 4:125

27.

Rose C, Vtoraya O, Pluzanska A, Neave F, Clemens M, Chaudri-Ross HA, Wyld P, Lang R (2002) Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer (abstract 131). Proc Am Soc Clin Oncol

28.

Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217CrossRefPubMed

29.

Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811PubMed

30.

Sivaraman L, Conneely OM, Medina D, O'Malley BW (2001) p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci U S A 98:12379CrossRefPubMed

31.

Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC (1994) Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86:431PubMed

32.

Wattenberg LW (1966) Chemoprophylaxis of carcinogenesis: a review. Cancer Res 26:1520PubMed

33.

Weitzel JN, Pike MC, Ursin G, Daniels JR, Daniels AM, MacDonald DJ, Blazer KR, Spicer DV (2002) Proof of principle: mammographic density reduced by a gonadotrophin-releasing hormone agonist (GnRHA)-based chemoprevention regimen for young women at high risk for breast cancer. Breast Cancer Res Treat 76 [Suppl 1]:A414

34.

Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, Moscarelli E (2002) Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 90:1204

Title: New approaches to the endocrine prevention and treatment of breast cancer
Authors: Anthony Howell
Sacha J. Howell
D. Gareth Evans
Publication date: 01-06-2003
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue Special Issue 1/2003
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-003-0645-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2003

Anticancer drug development at the US National Cancer Institute

Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics

Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms

Thymidylate synthase inhibitors as anticancer agents: from bench to bedside

Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer